Pharamacokinetic modeling for boronophenylalanine-fructose mediated neutron capture therapy: 10B concentration predictions and dosimetric consequences.
A two-compartment open model has been developed for predicting 10B concentrations in blood following intravenous infusion of the L-p-boronophenylalanine-fructose complex in humans and derived from pharmacokinetic studies of 24 patients in Phase I clinical trials of boron neutron capture therapy. The 10B concentration profile in blood exhibits a characteristic rise during the infusion to a peak of approximately 32 microg/g (for infusion of 350 mg/kg over 90 min) followed by a biexponential disposition profile with harmonic mean half-lives of 0.32 +/- 0.08 and 8.2 +/- 2.7 h, most likely due to redistribution and primarily renal elimination, respectively. The mean model rate constants k12, k21, and k10 are (mean +/- SD) 0.0227 +/- 0.0064 min(-1), 0.0099 +/- 0.0027 min(-1), 0.0052 +/- 0.0016 min(-1), respectively, and the central compartment volume of distribution V1 is 0.235 +/- 0.042 L/kg. In anticipation of the initiation of clinical trials using an intense neutron beam with concomitantly short irradiations, the ability of this model to predict, in advance, the average blood 10B concentration during brief irradiations was simulated in a retrospective analysis of the pharmacokinetic data from these patients. The prediction error for blood boron concentration and its effect on simulated dose delivered for each irradiation field are reported for three different prediction strategies. In this simulation, error in delivered dose (or, equivalently, neutron fluence) for a given single irradiation field resulting from error in predicted blood 10B concentration was limited to less than 10%. In practice, lower dose errors can be achieved by delivering each field in two fractions (on two separate days) and by adjusting the second fraction's dose to offset error in the first.
Kiger
W S
WS
Nuclear Reactor Laboratory, Massachusetts Institute of Technology, Cambridge, MA, USA. wskiger@mit.edu
Palmer
M R
MR
Riley
K J
KJ
Zamenhof
R G
RG
Busse
P M
PM
D001895:Boron / Q000032:analysis / Q000097:blood*; D001896:Boron Compounds / Q000493:pharmacokinetics*; D016754:Boron Neutron Capture Therapy / Q000379:methods; D001932:Brain Neoplasms / Q000532:radiotherapy / Q000556:secondary; D005909:Glioblastoma / Q000532:radiotherapy; D006207:Half-Life; D006801:Humans; D008545:Melanoma / Q000532:radiotherapy; D008962:Models, Theoretical; D011237:Predictive Value of Tests; D011879:Radiotherapy Dosage; D012878:Skin Neoplasms / Q000532:radiotherapy
D001896:Boron Compounds; D001895:Boron